The implications of oncogene expression on cancer drug resistance remain poorly understood, although there have been over 25 oncogenes including KRAS, ERBB2, PIK3CA, AKT hypothesized to contribute to drug resistance in ovarian cancer through various signalling pathways [215, 216, 224]. The gene discussed is ERBB2; the disease is cancer.